ENTA (Enanta Pharmaceuticals) Cash per Share: $6.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTA Enanta Pharmaceuticals Inc ENTA
49 GF Score
Price $14.08
GF Value $7.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cash per Share?

Enanta Pharmaceuticals ENTA -0.14% 49 Cash per Share is $6.51 as of Jun. 2026. GuruFocus rates ENTA with a GF Score™ of 49/100 and a GF Value™ of $7.93 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Enanta Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 was $6.51.

Enanta Pharmaceuticals  (NAS:ENTA) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Enanta Pharmaceuticals Cash per Share Related Terms

Enanta Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cash per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.06 11.99 17.57 11.71 8.83

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.55 8.83 6.40 5.64 6.51
ENTA
49GF Score
Enanta Pharmaceuticals Inc ENTA
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Enanta Pharmaceuticals's Cash per Share for the fiscal year that ended in Sep. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=188.864/21.39
=8.83

Enanta Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=189.506/29.12
=6.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $6.51 mean?
Enanta Pharmaceuticals (ENTA) has a Cash per Share of $6.51 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Cash per Share too high?
Enanta Pharmaceuticals' current Cash per Share is $6.51. Overall, Enanta Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Cash per Share compare to CMPX and CCCC?
Enanta Pharmaceuticals' Cash per Share of $6.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Cash per Share is $6.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.93, compared to a current price of $14.08 — trading 77.6% above its estimated fair value. The current Cash per Share is $6.51. Enanta Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Cash per Share is $6.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of $14.08 is trading 77.6% above its estimated GF Value™ of $7.93. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ENTA:

  • Cash per Share: $6.51
  • GF Value™: $7.93 vs. price of $14.08 (77.6% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges 9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
49GF Score

Get the complete analysis for ENTA

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.08
Price
$7.93
GF Value